Notal Vision partners with AsclepiX to provide home OCT monitoring
Click Here to Manage Email Alerts
Notal Vision will provide home OCT monitoring services to support the CONGO and SHASTA phase 1 trials studying AsclepiX’s AXT107 in patients with retinal diseases, according to a press release.
The partnership will augment the phase 1 clinical trial data by contributing data points obtained by study patients at home between scheduled clinic visits.
Patients with diabetic macular edema and age-related macular will use the Notal Home OCT device daily, imaging data will be transmitted to the secure Notal Health Cloud, and the Notal OCT Analyzer will quantify intraretinal and subretinal fluid in each volume scan, according to the release.
“Remote OCT monitoring of patients with exudative retinal diseases in a regulatory clinical trial allows AsclepiX Therapeutics to capture critical data points while potentially reducing the burden of frequent office visits,” study investigator Arshad M. Khanani, MD, said in the release. “The clinical value and potential benefit of such an approach is even more crucial now in light of the COVID-19 pandemic.”
Read more about
Click Here to Manage Email Alerts